An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights
for Covid-19 interventions between the pharmaceutical industry and developing nations endures.
At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries
when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected.
In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry
collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers &
Associations (IFPMA).
The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved
in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck.
The declaration is not legally binding.
However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.
General practitioners (GPs) across England have made a resolute stand against proposed alterations in the 2024/25 national GP General Medical Services (GMS)
contract put forth by the Department of Health and Social Care (DHSC) and NHS England.
This firm opposition coincides with the declaration of an extended six-month strike by 33,869 junior doctors within the NHS, advocating for full pay reinstatement
and reforms in the pay recommendation process.
The latest survey conducted by the British Medical Association (BMA) has revealed that an overwhelming 99.2% of GPs in England are against any changes to the
existing contract.
The proposed amendments, slated for implementation from April 1st, 2024, encompass a meagre national practice contract baseline funding uplift of just 1.9%,
notably falling short of recent inflation rates.
This corroborates with GP Online poll that recently unveiled widespread GP dissatisfaction with proposed changes to the national GMS contract. 83% of GPs in
favour of strikes cite pay and funding concerns, while burnout, high workloads, and patient safety also fuel discontent.
The Self-Care Strategy Group (SCSG) has written to Health Secretary, Wes Streeting, urging the new Labour government to fully realize self-care's benefits.
With PAGB serving as the secretariat for the Group, signatories of the letter also include CPE, RPS, CCA, NPA, the Dispensing Doctors' Association, the National
Association of Primary Care, the Patient Information Forum, and the Self Care Forum.
The nine members highlight the importance of collaborative efforts to build an NHS fit for the future.
In the letter, the group emphasises the potential of self-care to alleviate pressure on primary and emergency healthcare services.
They call for expanded prescribing rights, optimised digital health tools, and streamlined referral processes between primary, diagnostic, and specialist care
services.
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics.
On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model.
Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face.
"To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.
Members of the Pharmacists' Defence Association (PDA) who have benefits in the Boots Pension Scheme have sought support from their union following the recent
communications from the trustees about the removal of the option to retire at 60 without a reduced pension.
The company claimed that retirement between 60-65 years old without a reduced pension was a discretionary benefit, and it has ended with the buy-in deal with Legal
and General.
However, PDA members believe there is insufficient evidence to fully support this claim, and therefore they are questioning whether this option should have been
secured as part of the buy in and not ended with immediate effect.
PDA Union national officer, Paul Moloney said: "Instead, we believe benefit statements issued to members, at the very least are contradictory, and clearly state
that a full pension will be payable from a member's 60th birthday, with no reference to this benefit being discretionary and therefore subject to a regular
review by the trustees. Instead, the benefit statements give the impression that an unreduced pension from 60 is a right with no indication that retirement plans
should not be based on the benefit statements."
The Association of the British Pharmaceutical Industry (ABPI) has supported the Department of Health and Social Care's recommendation to 'aggressively expedite and roll out new medicines' that have gone through trials.
The ABPI welcomes government report on cancer services in England and the opportunity it provides to refocus how the pharmaceutical industry, NHS and government can improve the lives of cancer patients.
David Watson, executive director, Patient Access at the ABPI, said: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in NHS cancer care.
"We are pleased that the report reflects concerns about variable access to cancer medicines. We support the Committee's recommendations to 'aggressively expedite
and roll out new medicines' that have gone through trials and to ensure regulatory innovation results in swift uptake in the UK.
The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new
antibiotics' by the Office of Health Economics (OHE).
OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire
research and development process for a new antibiotic.
The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics.
In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising
pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing
AMR research.
In significant development, the Pharmacists' Defence Association (PDA) has advised its Boots members to challenge the "trustees' decision to end the
ability to take an unreduced pension from age 60 by submitting complaints through the scheme's two-stage internal disputes procedure".
The issue centers around the alterations made to pension scheme rules without the adequate disclosure to scheme members or their representatives.
The PDA has drafted template letters to assist scheme members in response to undisclosed changes during a buyout process, sparking legal challenges and demands
for transparency from Boots and scheme trustees.
Paul Moloney, National Officer of the PDA Union leading the campaign, expressed concern over the sudden withdrawal of the right to an unreduced pension from age 60.
"We have always maintained that members had a right under the rules to draw an unreduced pension from age 60," Moloney stated.
A groundbreaking study analysing data from nearly 600,000 cancer patients in England has shed light on the increased risk of second cancers among breast
cancer survivors.
The research conducted by University of Cambridge in association with the Lancet Regional Health-Europe studied data from over 580,000 female and over 3,500 male
breast cancer survivors diagnosed between 1995 and 2019 using the National Cancer Registration Dataset.
The findings suggest that survivors of breast cancer, the most prevalent cancer in the UK, face a substantially higher risk of developing second primary cancers.
According to the research, female survivors exhibited a twofold increase in the risk of contralateral breast cancer compared to the general population.
The data highlighted an 87 per cent greater risk of endometrial cancer, a 58 per cent greater risk of myeloid leukemia, and a 25 per cent greater risk of ovarian
cancer in female survivors.
Extending its support for the Prescription Charges Coalition (PCC), the Pharmacists' Defence Association (PDA) is asking pharmacists in England to share their
experiences of patients denying prescriptions due to financial issues.
PDA members who have practiced in the country within the last 12 months are asked to complete the Prescription Charges Coalition survey by Sunday 28 January.
The PCC is an alliance of more than 50 organisations campaigning to abolish unfair prescription charges for people with long-term conditions in England.
All members of the coalition, including PDA and Royal Pharmaceutical Society (RPS), understand that if patients do not receive their prescribed medicines due to the
cost, their health may deteriorate, and this can increase costs for the National Health Service (NHS).